{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:01:24Z","timestamp":1787828484713,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejca.2024.114146","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T01:56:55Z","timestamp":1717120615000},"page":"114146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non\u2013small cell lung cancer, and renal cell carcinoma"],"prefix":"10.1016","volume":"207","author":[{"given":"Jason J.","family":"Luke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi B.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A.","family":"Leiby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Krepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo F.","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Catherine Pietanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Samkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nageatte","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114146_bib1","series-title":"(pembrolizumab) injection, for intravenous use. 01\/2024","author":"KEYTRUDA","year":"2024"},{"key":"10.1016\/j.ejca.2024.114146_bib3","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114146_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114146_bib5","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","volume":"23","author":"Long","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114146_bib6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114146_bib7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114146_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114146_bib9","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"NEJM"},{"key":"10.1016\/j.ejca.2024.114146_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2020.11.010","article-title":"Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma","volume":"144","author":"Robert","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114146_bib11","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.2147\/DDDT.S146286","article-title":"Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials","volume":"11","author":"Wang","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ejca.2024.114146_bib12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","article-title":"Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies","volume":"135","author":"Nosaki","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2024.114146_bib13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.20.02363","article-title":"Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114146_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113530","article-title":"Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients","volume":"199","author":"Brahmer","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114146_bib15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114146_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114146_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Bottomley","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114146_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2022.08.004","article-title":"Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: health-related quality of life from the randomized phase 3 KEYNOTE-716 study","volume":"176","author":"Khattak","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114146_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/oncolo\/oyad231","article-title":"Patient-reported outcomes in KEYNOTE-564: adjuvant pembrolizumab versus placebo for renal cell carcinoma","volume":"29","author":"Choueiri","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114146_bib20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114146_bib21","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.114146_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100474","article-title":"Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis","volume":"7","author":"Kiss","year":"2022","journal-title":"ESMO Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:23:51Z","timestamp":1786969431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":21,"alternative-id":["S0959804924008025"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114146","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non\u2013small cell lung cancer, and renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. and The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114146"}}